- Home
- FOUR vs LQDA Comparison
FOUR vs LQDA Comparison
Compare FOUR & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FOUR | LQDA |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.1B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FOUR | LQDA |
|---|---|---|
| Price | $43.11 | $40.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 11 |
| Target Price | ★ $85.04 | $41.00 |
| AVG Volume (30 Days) | ★ 2.0M | 1.0M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,180,000,000.00 | $158,320,000.00 |
| Revenue This Year | $23.83 | $278.87 |
| Revenue Next Year | $14.30 | $57.13 |
| P/E Ratio | $27.53 | ★ N/A |
| Revenue Growth | 25.50 | ★ 1031.18 |
| 52 Week Low | $39.91 | $11.85 |
| 52 Week High | $107.16 | $46.67 |
Technical Indicators
Market Signals| Indicator | FOUR | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 43.13 | 62.68 |
| Support Level | $41.96 | $31.75 |
| Resistance Level | $76.31 | $46.67 |
| Average True Range (ATR) | 3.45 | 1.91 |
| MACD | 0.17 | 0.41 |
| Stochastic Oscillator | 18.68 | 88.40 |
Price Performance
Historical ComparisonAbout FOUR Shift4 Payments Inc.
Shift4 Payments Inc is provider of integrated payment processing and technology solutions. The company offers software providers a single integration to an end-to-end payments offering, a powerful gateway and a robust suite of technology solutions (including cloud enablement, business intelligence, analytics, and mobile) to enhance the value of their software suites and simplify payment acceptance. The company derives maximum revenue from United States.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.